Title: Robert George Holgate: Innovator in Antibody Development
Introduction
Robert George Holgate is a notable inventor based in Great Britain, recognized for his contributions to the field of biotechnology, particularly in the development of humanized antibodies. Despite having no patents registered under his name, his work has significantly impacted cancer treatment and diagnostics.
Latest Patents
Holgate's latest patents include "Humanized Antibodies Against Ceacam1," which details humanized antibodies capable of specific binding to human CEACAM1 molecules. These antibodies, along with their encoding polynucleotide sequences, are crucial for pharmaceutical compositions aimed at treating and diagnosing cancer and other conditions. Another significant patent is "Antibody Specific For CD22 And Methods Of Use Thereof," which provides antibodies specific for an epitope present on CD22. These antibodies are useful in various treatment, diagnostic, and monitoring applications, with some capable of inducing apoptosis in cells expressing CD22 on their surface.
Career Highlights
Throughout his career, Holgate has worked with prominent companies in the biotechnology sector, including Redwood Bioscience, Inc. and Famewave Ltd. His innovative approaches and research have contributed to advancements in antibody therapies.
Collaborations
Holgate has collaborated with notable professionals in the field, including David Rabuka and Francis Joseph Carr. These partnerships have further enhanced his research and development efforts.
Conclusion
Robert George Holgate's work in the development of humanized antibodies showcases his commitment to advancing medical science, particularly in cancer treatment. His contributions, although not reflected in a number of patents, are significant in the biotechnology landscape.